-
Mashup Score: 2
Objective Urine proteomic approaches have shown promise in identifying biological pathways in lupus nephritis (LN) which are not captured on renal histopathology or by measurement of proteinuria alone. We investigated how the urine proteome changes with treatment response and with belimumab therapy. Methods Urine samples from 54 Belimumab International Systemic Lupus Erythematosus–Lupus…
Source: Lupus Science & MedicineCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 2
Objective Urine proteomic approaches have shown promise in identifying biological pathways in lupus nephritis (LN) which are not captured on renal histopathology or by measurement of proteinuria alone. We investigated how the urine proteome changes with treatment response and with belimumab therapy. Methods Urine samples from 54 Belimumab International Systemic Lupus Erythematosus–Lupus…
Source: Lupus Science & MedicineCategories: Latest Headlines, RheumatologyTweet-
1st study to examine the effect of #belimumab, on the #urine proteome in LN: data shows #shifts in profiles are seen with belimumab therapy, with results suggesting that future studies modulation of CD23-mediated immune enhancement pathways in LN response. https://t.co/mMUeiPAsIn
-
-
Mashup Score: 4
Introduction Lupus nephritis (LN) is more prevalent in patients with SLE of Asian ethnicity than in Caucasian patients. Belimumab became available in Japan in 2017 to treat patients with SLE, including those with LN. In the BLISS-LN trial ([NCT01639339][1]), belimumab showed a favourable effect on renal outcomes when combined with standard therapy (ST) starting at the induction treatment phase…
Source: Lupus Science & MedicineCategories: Latest Headlines, RheumatologyTweet-
Postmarketing #study & #Lupus #Registry of #Nationwide Institutions, the #MOONLIGHT study explore effectiveness of #belimumab + ST by examining risk reduction in renal flare, ability to taper #corticosteroid treatment & #systemic responsiveness 3yrs after https://t.co/YGbo8x8WEs
-
-
Mashup Score: 2
Introduction Lupus nephritis (LN) is more prevalent in patients with SLE of Asian ethnicity than in Caucasian patients. Belimumab became available in Japan in 2017 to treat patients with SLE, including those with LN. In the BLISS-LN trial ([NCT01639339][1]), belimumab showed a favourable effect on renal outcomes when combined with standard therapy (ST) starting at the induction treatment phase…
Source: Lupus Science & MedicineCategories: Latest Headlines, RheumatologyTweet-
Postmarketing #study & #Lupus #Registry of #Nationwide Institutions, the #MOONLIGHT study explore effectiveness of #belimumab + ST by examining risk reduction in renal flare, ability to taper #corticosteroid treatment & #systemic responsiveness 3yrs after https://t.co/YGbo8x8WEs
-
-
Mashup Score: 9Belimumab is not associated with COVID-19 mRNA vaccination failure in systemic lupus erythematosus - 2 year(s) ago
Dear Editor, in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, patients with autoimmune-mediated rheumatic diseases (ARD) may have a
Source: OUP AcademicCategories: Latest Headlines, RheumatologyTweet-
On #Belimumab & #SLE, we have two letters for you this Friday! 1️⃣ Belimumab not associated with #COVID19 mRNA vax failure https://t.co/TvqMUfW17M 2️⃣ Tapering safe with stable activity in a single-centre from @micaela_fredi et al. https://t.co/mIPhAZHypv
-
-
Mashup Score: 0
The FDA has approved GlaxoSmithKline’s belimumab for the treatment of children with active lupus nephritis who are also receiving standard therapy, according to a company press release.
Source: www.healio.comCategories: Latest Headlines, RheumatologyTweet-
ICYMI: The @US_FDA has approved GlaxoSmithKline’s #belimumab for the treatment of children with active #lupus nephritis who are also receiving standard therapy https://t.co/QhHfR3Pf3g
-
-
Mashup Score: 0
The FDA has approved GlaxoSmithKline’s belimumab for the treatment of children with active lupus nephritis who are also receiving standard therapy, according to a company press release.
Source: www.healio.comCategories: Latest Headlines, RheumatologyTweet-
ICYMI: The @US_FDA has approved GlaxoSmithKline’s #belimumab for the treatment of children with active #lupus nephritis who are also receiving standard therapy https://t.co/QhHfR3Pf3g
-
-
Mashup Score: 1
The FDA has approved GlaxoSmithKline’s belimumab for the treatment of children with active lupus nephritis who are also receiving standard therapy, according to a company press release.
Source: www.healio.comCategories: General Medicine News, Latest HeadlinesTweet-
The @US_FDA has approved GlaxoSmithKline’s #belimumab for the treatment of children with active #lupus nephritis who are also receiving standard therapy https://t.co/3l0Y6F7nzA
-
The @US_FDA has approved GlaxoSmithKline’s #belimumab for the treatment of children with active #lupus nephritis who are also receiving standard therapy https://t.co/QhHfR3Pf3g
-
-
Mashup Score: 0
Until now, there has been limited information on the long-term safety and efficacy of belimumab in Chinese patients with systemic lupus erythematosus.
Source: Rheumatology NetworkCategories: Latest Headlines, RheumatologyTweet-
Disease control, as well as safety data, was achieved and maintained in patients with systemic #lupus erythematosus receiving #belimumab for ≤6 years. https://t.co/917M8CUj13
-
-
Mashup Score: 0
Until now, there has been limited information on the long-term safety and efficacy of belimumab in Chinese patients with systemic lupus erythematosus.
Source: Rheumatology NetworkCategories: Latest Headlines, RheumatologyTweet-
Until now, there has been limited information on the long-term safety and efficacy of #belimumab in Chinese patients with systemic #lupus erythematosus. #SLE https://t.co/iBWF0F7Pgv
-
1st study to examine the effect of #belimumab, on the #urine proteome in LN: data shows #shifts in profiles are seen with belimumab therapy, with results suggesting that future studies modulation of CD23-mediated immune enhancement pathways in LN response. https://t.co/mMUeiPiRjN